JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269103

Recombinant human UBE2I / UBC9 protein (Active)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant human UBE2I / UBC9 protein (Active) is a Human Full Length protein, expressed in Escherichia coli, with >95%, suitable for SDS-PAGE, FuncS.

View Alternative Names

UBC9, UBCE9, UBE2I, SUMO-conjugating enzyme UBC9, RING-type E3 SUMO transferase UBC9, SUMO-protein ligase, Ubiquitin carrier protein 9, Ubiquitin carrier protein I, Ubiquitin-conjugating enzyme E2 I, Ubiquitin-protein ligase I, p18

2 Images
Functional Studies - Recombinant human UBE2I / UBC9 protein (Active) (AB269103)
  • FuncS

Supplier Data

Functional Studies - Recombinant human UBE2I / UBC9 protein (Active) (AB269103)

The specific activity of ab269103 was 200 nmol/min/mg in a UBE2I assay using human SUMO2 and RanGAP1 as substrate.

SDS-PAGE - Recombinant human UBE2I / UBC9 protein (Active) (AB269103)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant human UBE2I / UBC9 protein (Active) (AB269103)

SDS-PAGE analysis of ab269103.

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

FuncS, SDS-PAGE

applications

Biologically active

Yes

Biological activity

The specific activity of ab269103 was determined to be 200 nmol/min/mg in a UBE2I assay using human SUMO2 and RanGAP1 as substrate.

Accession

P63279

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7 Preservative: 1.02% Imidazole Constituents: 25% Glycerol (glycerin, glycerine), 1.74% Sodium chloride, 0.82% Sodium phosphate, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.002% PMSF

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"linker":null,"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":"P63279","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

Properties and storage information

Form
Liquid
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
True

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBE2I also known as UBC9 is a small ubiquitin-related modifier (SUMO) conjugating enzyme. It plays an important role in the SUMOylation process which modifies proteins by attaching sumo proteins to them altering their function. This protein has a molecular mass of approximately 18 kDa. UBE2I is expressed broadly across various tissues demonstrating its significance in cellular processes.
Biological function summary

The SUMO conjugating enzyme UBE2I is part of the SUMOylation complex which includes the SUMO E1 enzyme and SUMO E3 ligase. It facilitates the attachment of SUMO proteins to target proteins which can influence protein stability localization and interaction with other proteins. This modification usually regulates important cellular functions such as transcription DNA repair and cell cycle progression.

Pathways

Proteins modified by UBE2I participate in significant biological pathways such as the DNA damage response and cell cycle regulation. In the DNA damage response UBE2I works with proteins such as p53 and BRCA1 to maintain genomic stability. In cell cycle pathways interactions with proteins like cyclin D1 and CDK inhibitors help control cellular proliferation by SUMOylating key regulatory proteins.

UBE2I has been implicated in cancer and neurodegenerative diseases. Altered SUMOylation by UBE2I can lead to the dysfunction of tumor suppressor proteins like p53 contributing to cancer development. In neurodegenerative diseases abnormal SUMOylation might affect proteins like tau which can lead to the progression of conditions such as Alzheimer's disease. The role of UBE2I in these disorders highlights it as a potential therapeutic target in addressing these conditions.

General info

Function

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity (PubMed : 26620705). Sumoylates SHMT1 at 'Lys-38' or 'Lys-39' leading to RAN-dependent nuclear import of SHMT1 (PubMed : 17446168). Also sumoylates TYMS and DHFR (PubMed : 18067453).

Sequence similarities

Belongs to the ubiquitin-conjugating enzyme family.

Post-translational modifications

Phosphorylation at Ser-71 significantly enhances SUMOylation activity.

Subcellular localisation

Nucleus

Product protocols

Target data

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity (PubMed : 26620705). Sumoylates SHMT1 at 'Lys-38' or 'Lys-39' leading to RAN-dependent nuclear import of SHMT1 (PubMed : 17446168). Also sumoylates TYMS and DHFR (PubMed : 18067453).
See full target information UBE2I

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com